Head-to-head evidence
Alimatravir vs Ulonivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Alimatravir
Developed by Merck & Co.
NCT06045507 · Phase 2 · completed
The study randomized 352 participants to three MK-8527 dose groups or matched placebo and used double blinding, but Alimatravir was not studied and was not the comparator. Its primary endpoints were safety outcomes rather than efficacy, and the registry provides counts without statistical comparisons, so whether the primary comparisons were met cannot be determined.
Next expected readout: January 2027 · NCT07600775 (registry estimate)
Ulonivirine
Developed by Merck & Co.
NCT04564547 · Phase 2 · completed
Randomized, triple-masked phase 2b switch study of once-weekly islatravir plus ulonivirine in virologically suppressed HIV-1 infection (161 participants). All three primary endpoints are adverse-event rates reported descriptively; no efficacy comparison was posted as primary.
Next expected readout: August 2027 · NCT06891066 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alimatravir's landscape · Ulonivirine's landscape